Nanoviricides Inc Quick Ratio (NNVC) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nanoviricides inc   (NYSE: NNVC)

Nanoviricides Inc 's Quick Ratio

NNVC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Nanoviricides Inc 's Cash & cash equivalent grew by 106.17 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Nanoviricides Inc 's Quick Ratio to 3.02, Quick Ratio remained below Nanoviricides inc average.

Within Major Pharmaceutical Preparations industry 224 other companies have achieved higher Quick Ratio than Nanoviricides Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 100 to 842.

Explain Quick Ratio?
How much Cash & cash equivalents NNVC´s has?
What are NNVC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NNVC Quick Ratio (Mar 31 2026)
Q3		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4		 (Mar 31 2025)
Q3
Y / Y Current Liabilities Change -11.14 % -3.85 % -27.58 % -3.85 % 47.41 %
Y / Y Cash & cash equivalent Change 26.38 % -67.51 % -70.88 % -67.51 % -21.94 %
Quick Ratio MRQ 3.02 1.19 0.95 1.19 2.12
NNVC's Total Ranking # 842 # 100 # 1262 # 1349 # 998
Seq. Current Liabilities Change -18.45 % 10.5 % -9.5 % 8.97 % -11.77 %
Seq. Cash & cash equivalent Change 106.17 % 38.45 % -27.77 % -38.7 % -47 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 225
Healthcare Sector # 373
Overall Market # 842


Quick Ratio Statistics
High Average Low
64.81 16.32 0.25
(Mar 31 2015)   (Dec 31 2019)




Financial Statements
Nanoviricides Inc 's Current Liabilities $ 1 Millions Visit NNVC's Balance sheet
Nanoviricides Inc 's Cash & cash equivalent $ 3 Millions Visit NNVC's Balance sheet
Source of NNVC's Sales Visit NNVC's Sales by Geography


Cumulative Nanoviricides Inc 's Quick Ratio

NNVC's Quick Ratio for the trailling 12 Months

NNVC Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -12.41 % -3.28 % 16.31 % 50.41 % 96.07 %
Y / Y Cash & cash equivalent TTM Growth -53.41 % -59.42 % -50.05 % -44.92 % -39.67 %
Quick Ratio TTM 1.53 1.36 1.99 2.32 2.88
Total Ranking TTM # 2793 # 914 # 2424 # 3008 # 3094
Seq. Current Liabilities TTM Growth -2.67 % -1.04 % -8.19 % -0.94 % 7.47 %
Seq. Cash & cash equivalent TTM Growth 9.88 % -32.31 % -21.47 % -20.24 % -4.27 %

Quick ratio ranking by company, industry and sector >> Back to NNVC Financial Strength Comparisons >> Go to Compare NNVC Quick Ratio to its Competitors

On the trailing twelve months basis NNVC Cash & cash equivalent grew by 26.38 % in Q3 2026 year on year, while Current Liabilities faded to $1 millions, this led to increase in in Nanoviricides Inc 's Quick Ratio to 1.53, Quick Ratio remained below NNVC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 388 other companies have achieved higher Quick Ratio than Nanoviricides Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 914 to 2793.

Explain Quick Ratio?
How much Cash & cash equivalents NNVC´s has?
What are NNVC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 389
Healthcare Sector # 793
Within the Market # 2793


trailing twelve months Quick Ratio Statistics
High Average Low
37.47 11.51 0.8
(Mar 31 2022)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Capricor Therapeutics inc   8.28 $ 278.610  Millions$ 33.637  Millions
Eledon Pharmaceuticals Inc   8.25 $ 111.089  Millions$ 13.458  Millions
Corbus Pharmaceuticals Holdings Inc   8.16 $ 138.219  Millions$ 16.933  Millions
Biovie Inc   8.13 $ 13.099  Millions$ 1.611  Millions
Aardvark Therapeutics Inc   8.09 $ 91.200  Millions$ 11.268  Millions
Lite Strategy Inc   7.92 $ 7.544  Millions$ 0.952  Millions
Atea Pharmaceuticals Inc   7.82 $ 256.006  Millions$ 32.733  Millions
Bullfrog Ai Holdings Inc   7.79 $ 5.080  Millions$ 0.652  Millions
Moonlake Immunotherapeutics  7.76 $ 357.921  Millions$ 46.114  Millions
Korro Bio Inc   7.71 $ 113.970  Millions$ 14.787  Millions
Xenetic Biosciences Inc   7.67 $ 7.347  Millions$ 0.958  Millions
Mineralys Therapeutics Inc   7.66 $ 112.779  Millions$ 14.718  Millions
Centessa Pharmaceuticals Plc  7.56 $ 276.589  Millions$ 36.574  Millions
Adicet Bio Inc   7.52 $ 137.592  Millions$ 18.298  Millions
Cartesian Therapeutics Inc   7.44 $ 118.641  Millions$ 15.945  Millions
Q32 Bio Inc   7.36 $ 50.751  Millions$ 6.892  Millions
Ibio inc   7.32 $ 47.641  Millions$ 6.504  Millions
Anaptysbio Inc   7.24 $ 286.455  Millions$ 39.582  Millions
Avalo Therapeutics Inc   7.08 $ 82.140  Millions$ 11.599  Millions
Alx Oncology Holdings Inc  6.95 $ 140.324  Millions$ 20.178  Millions
Lyell Immunopharma Inc   6.88 $ 254.023  Millions$ 36.947  Millions
Zymeworks Inc   6.85 $ 244.282  Millions$ 35.649  Millions
Telomir Pharmaceuticals Inc   6.72 $ 5.561  Millions$ 0.827  Millions
Biohaven Ltd   6.68 $ 347.817  Millions$ 52.075  Millions
Silence Therapeutics Plc  6.63 $ 90.590  Millions$ 13.668  Millions
Dermata Therapeutics Inc   6.60 $ 6.945  Millions$ 1.053  Millions
Azitra Inc   6.49 $ 10.051  Millions$ 1.550  Millions
Sionna Therapeutics Inc   6.48 $ 63.324  Millions$ 9.776  Millions
Assembly Biosciences Inc   6.47 $ 226.601  Millions$ 34.997  Millions
Renovorx Inc   6.44 $ 12.362  Millions$ 1.920  Millions

Date modified: 2026-09-04T10:33:11+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.